department of pharmacology



Stephen K. Burley, M.D., D.Phil., F.R.S.C.

Chief Scientific Officer and Senior Vice-President Research
SGX Pharmaceuticals, Inc.
San Diego, CA


Stephen Burley is the chief scientific officer of SGX Pharmaceuticals, Inc., located in San Diego, California. SGX is an oncology focused drug discovery and development company, with Troxatyl® in clinical trials and multiple protein kinase inhibitors in preclinical development, including compounds targeting imatinib resistant BCR-ABL. Prior to joining SGX, Burley was the Richard M. and Isabel P. Furlaud professor and chief academic officer at The Rockefeller University, and a full investigator in the Howard Hughes Medical Institute. He has authored or coauthored more than 160 scholarly scientific articles. He is a fellow of the Royal Society of Canada and of the New York Academy of Sciences. Burley received an M.D. degree from Harvard Medical School in the joint Harvard-MIT Health Sciences and Technology program and, as a Rhodes Scholar, received a D.Phil. in Molecular Biophysics from Oxford University. He trained in internal medicine at the Brigham and Women's Hospital, and did post-doctoral work with William N. Lipscomb at Harvard University and Gregory A. Petsko at the Massachusetts Institute of Technology. With William J. Rutter and others at the University of California, San Francisco and The Rockefeller University, Burley co-founded Prospect Genomics, Inc., which was subsequently acquired by SGX.